Alaunos rises as obesity‑drug data in mice shows weight loss

Shares of Alaunos Therapeutics TCRT.O jump 18.8% to $3.79

Drug developer says its experimental drug, ALN1003, helped obese mice lose weight in preclinical studies; obesity is a chronic condition marked by excess body fat

Co says mice lost up to 13% body weight and showed healthier liver tissue

Drug is non-hormonal, unlike GLP-1 drugs; mice on high-fat diets ate less and lost more fat, co says

Mild, temporary activity changes were seen; two high-dose mice were slightly dehydrated, but were healthy, per co

Shares up 70% in 2025